Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
Prothena to Report First Quarter 2024 Financial Results on May 8
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Prothena Announces Appointment of Daniel G. Welch as Director & Chair Designate
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs